A Phase 2 interventional study of Inclisiran sodium and Placebo in Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.
Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 5 that started in 2021, is one of 2 in phase 2, and was the 7th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Duke University · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 375 across the 24 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
36 studies in Hypercholesterolemia by Novartis: 6 open now, 10 under way, 5 of them phase 3. Of 26 finished, 10 (38%) have results posted.
Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 18th largest by enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2021, is one of 2 in phase 2, and was the 12th registered.
Novartis’s Hypercholesterolemia studies by the year they started, since 2002.
5 of the studies testing inclisiran in Hypercholesterolemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 24 studies testing inclisiran in Hypercholesterolemia, from their registry updates:
Among Novartis’s 36 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
This was a placebo-controlled, double-blind, randomized trial in Japanese participants with history of coronary artery disease (CAD) or participants categorized in 'high risk' by JAS 2017 guideline, or Japanese participants with heterozygous familial hypercholesterolemia (HeFH) and elevated Low-density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of statin(s) to evaluate the efficacy, safety, tolerability, and PK of subcutaneous inclisiran injection(s).
The expected duration of the participants' involvement in the study was approximately 374 days which included screening (up to 14 days), Day 1 study drug administration, two additional injections on Day 90 and Day 270, and the follow-up period to Day 360.
The primary analysis was conducted after all participants had finished Day 180 visit assessments or discontinued before Day 180 visit.
After the primary analysis, double-blind treatment period were maintained to Day 360, although specific sponsor members (except for blinded monitors) were unblinded for the regulatory submission in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection
Drug: Inclisiran sodium
Subcutaneous injection
Drug: Inclisiran sodium
Subcutaneous injection
Drug: Inclisiran sodium
Subcutaneous injection
Drug: Placebo
Subcutaneously injected on Day 1, 90 and 270.
Also known as: KJX839
Subcutaneously injected on Day 1, 90, and 270.
Also known as: KJX839 placebo
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180
Percent change from baseline in LDL-C was calculated to evaluate the effect of inclisiran at Day 180. Difference between different inclisiran dose groups and the placebo group in percentage change in LDL-C levels from baseline to Day 180 were calculated to capture both, the effect of the study drug and the effect of additional medications, mirroring the conditions in clinical practice. An MMRM (Mixed-effect Model with Repeated Measurement) was used as the primary analysis model, with treatment group, visits, interaction between visits and treatment groups, current use of statins or other lipid-modifying therapies as fixed effects, and baseline LDL-C as a continuous covariate.
Time frame: Baseline, Day 180
Percent Change From Baseline in PCSK9 by Visit
Percent change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) was calculated to evaluate the effect of inclisiran over time.
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in LDL-C by Visit
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran over time.
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120 and day 150
Absolute Change in LDL-C From Baseline at Day 180
Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran until Day 180.
Time frame: Baseline, Day 180
Proportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 180
Proportion of participants with LDL-C greater than 80% of baseline value at Day 180 was calculated to evaluate the effect of inclisiran until Day 180. Subjects are counted if the LDL-C value is greater than '0.8\*(LDL-C at Baseline - LDL-C at Day180) + LDL-C at Day180', or the LDL-C value is greater than or equal to the LDL-C at Baseline.
Time frame: Baseline, Day 180
Proportion of Participants With Greater or Equal to 50% LDL-C Reduction From Baseline by Visit
Proportion of participants with greater or equal to 50% LDL-C reduction from baseline was calculated to evaluate the effect of inclisiran over time.
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Cholesterol by Visit
Percent change from baseline in cholesterol by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Triglycerides by Visit
Percent change from baseline in triglycerides by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in HDL Cholesterol by Visit
Percent change from baseline in high-density lipoprotein cholesterol (HDL-C) by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Non-HDL Cholesterol by Visit
Percent change from baseline in non-HDL Cholesterol by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in VLDL-C by Visit
Percent change from baseline in very low-density lipoprotein cholesterol (VLDL - C) by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Apo- A1 by Visit
Percent change from baseline in Apolipoprotein A1 (Apo-A1) by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Apo- B by Visit
Percent change from baseline in Apolipoprotein B (Apo-B) by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Percent Change From Baseline in Lipoprotein-a by Visit
Percent change from baseline in Lipoprotein a (LP(a)) by visit was calculated to evaluate the effect of inclisiran over time
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
Proportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 180
Proportion of participants who attain lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines for their level of cardiovascular risk at Day 180 was calculated to evaluate the effect of inclisiran.
Time frame: Day 180
Number of Participants With LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL by Visit
Number of participants by LDL-C levels was calculated to evaluate the effect of inclisiran.
Time frame: Baseline, day 14, day 30, day 60, day 90, day 104, day 120, day 150, and day 180
| Milestone | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Started | 57 | 55 | 101 | 99 |
| Completed | 55 | 55 | 100 | 95 |
| Not completed | 2 | 0 | 1 | 4 |
| Withdrew: Subject decision | 1 | 0 | 0 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
Percent change from baseline in LDL-C was calculated to evaluate the effect of inclisiran at Day 180. Difference between different inclisiran dose groups and the placebo group in percentage change in LDL-C levels from baseline to Day 180 were calculated to capture both, the effect of the study drug and the effect of additional medications, mirroring the conditions in clinical practice. An MMRM (Mixed-effect Model with Repeated Measurement) was used as the primary analysis model, with treatment group, visits, interaction between visits and treatment groups, current use of statins or other lipid-modifying therapies as fixed effects, and baseline LDL-C as a continuous covariate.
| percent change in LDL-C | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) to Day 180 | 9.0 (3.5 to 14.5) | -47.6 (-53.4 to -41.8) | -51.9 (-56.8 to -47.0) | -56.3 (-61.1 to -51.4) |
Percent change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9) was calculated to evaluate the effect of inclisiran over time.
| percent change in PCSK9 | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 4.79 ± 21.623 | -55.42 ± 19.980 | -65.64 ± 13.677 | -69.56 ± 11.387 |
| Day 30 | 1.92 ± 22.427 | -66.45 ± 12.341 | -72.94 ± 8.809 | -76.46 ± 8.561 |
| Day 60 | -0.16 ± 22.656 | -62.56 ± 15.356 | -73.23 ± 10.692 | -76.52 ± 9.953 |
| Day 90 | 2.12 ± 21.447 | -59.76 ± 14.503 | -70.49 ± 10.806 | -73.09 ± 11.525 |
| Day 104 | 2.65 ± 28.624 | -69.05 ± 11.109 | -76.23 ± 9.017 | -78.55 ± 8.052 |
| Day 120 | 0.99 ± 21.572 | -70.29 ± 11.543 | -77.03 ± 8.206 | -79.80 ± 6.994 |
| Day 150 | 2.34 ± 23.353 | -66.02 ± 12.724 | -73.94 ± 17.139 | -77.12 ± 8.770 |
| Day 180 | 2.78 ± 21.226 | -63.62 ± 14.012 | -70.99 ± 10.495 | -75.97 ± 9.885 |
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran over time.
| percent change in LDL-C | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 1.68 ± 18.099 | -37.15 ± 21.855 | -42.08 ± 20.503 | -47.60 ± 19.889 |
| Day 30 | 1.29 ± 13.068 | -52.20 ± 18.389 | -55.54 ± 17.501 | -62.77 ± 15.097 |
| Day 60 | 0.24 ± 15.314 | -50.06 ± 19.173 | -55.61 ± 17.570 | -62.35 ± 13.976 |
| Day 90 | 2.69 ± 14.332 | -46.39 ± 17.872 | -53.92 ± 17.186 | -61.51 ± 15.480 |
| Day 104 | 1.20 ± 13.519 | -53.00 ± 19.001 | -60.33 ± 15.912 | -65.68 ± 15.321 |
| Day 120 | 2.26 ± 14.854 | -54.91 ± 19.410 | -62.04 ± 16.742 | -67.23 ± 16.017 |
| Day 150 | 4.27 ± 16.983 | -55.46 ± 18.817 | -60.55 ± 16.502 | -66.15 ± 15.197 |
Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran until Day 180.
| mg/dL | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Absolute Change in LDL-C From Baseline at Day 180 | 13.2 (6.6 to 19.8) | -49.3 (-56.2 to -42.3) | -53.9 (-59.8 to -48.0) | -57.7 (-63.5 to -51.8) |
Proportion of participants with LDL-C greater than 80% of baseline value at Day 180 was calculated to evaluate the effect of inclisiran until Day 180. Subjects are counted if the LDL-C value is greater than '0.8\*(LDL-C at Baseline - LDL-C at Day180) + LDL-C at Day180', or the LDL-C value is greater than or equal to the LDL-C at Baseline.
| Participants | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Proportion of Participants With LDL-C Greater Than 80% of Baseline Value at Day 180 | 35 | 0 | 0 | 0 |
Proportion of participants with greater or equal to 50% LDL-C reduction from baseline was calculated to evaluate the effect of inclisiran over time.
| Participants | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 1 | 17 | 40 | 45 |
| Day 30 | 0 | 31 | 63 | 83 |
| Day 60 | 0 | 26 | 64 | 75 |
| Day 90 | 0 | 22 | 58 | 76 |
| Day 104 | 0 | 32 | 77 | 82 |
| Day 120 | 0 | 37 | 72 | 82 |
| Day 150 | 0 | 35 | 73 | 78 |
| Day 180 | 0 | 33 | 68 | 73 |
Percent change from baseline in cholesterol by visit was calculated to evaluate the effect of inclisiran over time
| Percent change in cholesterol | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 0.87 ± 10.399 | -21.94 ± 14.034 | -24.71 ± 12.917 | -28.60 ± 12.476 |
| Day 30 | 0.89 ± 9.003 | -30.92 ± 12.558 | -32.90 ± 11.739 | -37.09 ± 10.227 |
| Day 60 | 0.31 ± 8.885 | -29.47 ± 13.426 | -33.71 ± 12.291 | -37.01 ± 9.948 |
| Day 90 | 1.03 ± 8.952 | -27.30 ± 13.127 | -32.26 ± 12.103 | -36.34 ± 10.655 |
| Day 104 | 1.62 ± 10.178 | -30.72 ± 13.239 | -35.63 ± 11.875 | -39.53 ± 10.468 |
| Day 120 | 1.11 ± 10.860 | -32.24 ± 13.575 | -36.24 ± 12.995 | -39.38 ± 10.165 |
| Day 150 | 2.41 ± 10.801 | -32.20 ± 14.246 | -35.70 ± 11.980 | -38.12 ± 10.850 |
| Day 180 | 2.78 ± 10.272 | -30.22 ± 12.468 | -32.95 ± 12.540 | -35.46 ± 11.941 |
Percent change from baseline in triglycerides by visit was calculated to evaluate the effect of inclisiran over time
| percent change in triglycerides | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 5.49 ± 28.803 | 1.24 ± 29.630 | -1.16 ± 51.241 | -7.19 ± 23.817 |
| Day 30 | 7.76 ± 35.248 | -4.72 ± 25.843 | -8.69 ± 25.450 | -8.37 ± 28.240 |
| Day 60 | 9.68 ± 37.000 | -7.17 ± 28.427 | -9.26 ± 27.598 | -9.93 ± 26.405 |
| Day 90 | 6.83 ± 33.204 | -1.87 ± 40.499 | -12.17 ± 26.204 | -9.99 ± 29.230 |
| Day 104 | 11.86 ± 37.365 | -7.12 ± 26.145 | -5.81 ± 55.419 | -13.51 ± 26.915 |
| Day 120 | 3.57 ± 33.870 | -9.40 ± 27.192 | -9.32 ± 33.471 | -12.33 ± 26.280 |
| Day 150 | 3.33 ± 32.023 | -5.60 ± 42.988 | -12.65 ± 24.766 | -11.81 ± 28.623 |
| Day 180 | -0.19 ± 32.161 | -2.34 ± 33.783 | -12.11 ± 39.414 | -13.67 ± 27.307 |
Percent change from baseline in high-density lipoprotein cholesterol (HDL-C) by visit was calculated to evaluate the effect of inclisiran over time
| percent change in HDL Cholesterol | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 1.73 ± 8.765 | 3.00 ± 10.745 | 5.93 ± 12.164 | 4.38 ± 10.727 |
| Day 30 | 1.94 ± 11.259 | 4.86 ± 10.450 | 9.89 ± 13.656 | 8.43 ± 12.740 |
| Day 60 | 0.57 ± 10.677 | 6.80 ± 15.222 | 8.02 ± 15.411 | 9.15 ± 14.984 |
| Day 90 | 0.56 ± 11.543 | 6.51 ± 16.297 | 10.86 ± 16.359 | 8.59 ± 16.546 |
| Day 104 | 1.35 ± 14.817 | 8.69 ± 15.303 | 11.04 ± 16.443 | 8.99 ± 17.280 |
| Day 120 | 4.20 ± 13.747 | 8.84 ± 13.432 | 12.65 ± 16.777 | 11.97 ± 18.300 |
| Day 150 | 5.12 ± 13.587 | 7.51 ± 17.455 | 12.80 ± 16.337 | 11.68 ± 18.486 |
| Day 180 | 8.25 ± 12.940 | 6.89 ± 17.051 | 15.95 ± 17.025 | 14.26 ± 20.158 |
Percent change from baseline in non-HDL Cholesterol by visit was calculated to evaluate the effect of inclisiran over time
| percent change in non-HDL Cholesterol | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 1.13 ± 13.511 | -31.37 ± 19.592 | -35.68 ± 18.056 | -41.16 ± 17.005 |
| Day 30 | 1.03 ± 11.483 | -44.72 ± 16.270 | -47.99 ± 15.318 | -54.17 ± 12.815 |
| Day 60 | 0.62 ± 11.841 | -43.39 ± 16.505 | -48.18 ± 15.146 | -54.10 ± 12.034 |
| Day 90 | 1.75 ± 11.931 | -39.83 ± 16.485 | -47.20 ± 15.002 | -53.18 ± 13.236 |
| Day 104 | 1.96 ± 12.067 | -46.10 ± 17.006 | -51.98 ± 14.344 | -57.74 ± 12.513 |
| Day 120 | 0.82 ± 14.045 | -48.22 ± 17.301 | -53.52 ± 15.425 | -58.67 ± 12.175 |
| Day 150 | 1.96 ± 13.519 | -47.90 ± 17.495 | -52.85 ± 14.254 | -56.82 ± 12.997 |
| Day 180 | 1.29 ± 13.455 | -44.83 ± 15.558 | -50.15 ± 16.446 | -54.04 ± 14.230 |
Percent change from baseline in very low-density lipoprotein cholesterol (VLDL - C) by visit was calculated to evaluate the effect of inclisiran over time
| percent change in VLDL-C | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 5.55 ± 28.428 | -2.96 ± 31.885 | -5.56 ± 43.055 | -12.41 ± 25.589 |
| Day 30 | 6.69 ± 33.655 | -9.01 ± 28.560 | -13.39 ± 28.081 | -14.74 ± 30.582 |
| Day 60 | 9.40 ± 36.824 | -10.27 ± 32.555 | -14.02 ± 28.944 | -17.94 ± 25.358 |
| Day 90 | 6.53 ± 33.387 | -5.39 ± 41.490 | -16.70 ± 26.127 | -15.76 ± 27.957 |
| Day 104 | 11.56 ± 37.588 | -12.10 ± 28.575 | -12.54 ± 45.978 | -24.05 ± 26.076 |
| Day 120 | 3.10 ± 33.707 | -15.90 ± 30.271 | -14.05 ± 36.083 | -22.29 ± 24.030 |
| Day 150 | 3.41 ± 31.791 | -10.91 ± 45.835 | -17.49 ± 27.270 | -18.39 ± 30.321 |
| Day 180 | -0.30 ± 31.345 | -7.30 ± 33.946 | -17.89 ± 33.050 | -21.74 ± 27.746 |
Percent change from baseline in Apolipoprotein A1 (Apo-A1) by visit was calculated to evaluate the effect of inclisiran over time
| percent change in Apo-A1 | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 0.04 ± 8.872 | 3.64 ± 9.293 | 2.29 ± 7.659 | 3.98 ± 7.952 |
| Day 30 | 0.90 ± 9.713 | 2.70 ± 10.553 | 4.52 ± 9.302 | 4.35 ± 9.012 |
| Day 60 | 0.00 ± 8.501 | 4.71 ± 11.785 | 3.89 ± 10.196 | 5.18 ± 10.023 |
| Day 90 | -0.35 ± 9.888 | 3.86 ± 11.353 | 5.71 ± 10.609 | 5.21 ± 10.383 |
| Day 104 | 0.14 ± 10.780 | 5.89 ± 13.922 | 5.66 ± 11.007 | 4.99 ± 10.061 |
| Day 120 | 1.79 ± 10.707 | 5.33 ± 12.293 | 6.49 ± 11.334 | 6.60 ± 11.152 |
| Day 150 | 3.70 ± 11.571 | 4.85 ± 14.330 | 7.46 ± 11.582 | 8.35 ± 12.564 |
| Day 180 | 6.09 ± 11.862 | 4.99 ± 14.170 | 10.26 ± 12.250 | 9.09 ± 13.871 |
Percent change from baseline in Apolipoprotein B (Apo-B) by visit was calculated to evaluate the effect of inclisiran over time
| percent change in Apo-B | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 1.09 ± 13.795 | -28.16 ± 16.442 | -32.45 ± 17.518 | -37.12 ± 16.743 |
| Day 30 | 2.16 ± 12.904 | -39.72 ± 14.749 | -43.99 ± 15.185 | -48.76 ± 12.962 |
| Day 60 | 1.41 ± 11.965 | -39.94 ± 13.996 | -44.49 ± 14.654 | -48.53 ± 12.005 |
| Day 90 | 2.76 ± 12.882 | -35.84 ± 14.134 | -42.04 ± 14.319 | -46.78 ± 12.611 |
| Day 104 | 3.03 ± 13.304 | -40.86 ± 14.578 | -47.03 ± 13.283 | -51.93 ± 12.390 |
| Day 120 | 2.05 ± 14.719 | -43.39 ± 14.174 | -48.18 ± 14.142 | -51.85 ± 12.414 |
| Day 150 | 3.86 ± 13.559 | -42.82 ± 14.799 | -46.71 ± 13.775 | -50.41 ± 12.411 |
| Day 180 | 3.82 ± 14.649 | -38.63 ± 13.265 | -44.50 ± 14.685 | -46.81 ± 13.968 |
Percent change from baseline in Lipoprotein a (LP(a)) by visit was calculated to evaluate the effect of inclisiran over time
| percent change in LP(a) | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14 | 3.33 ± 32.912 | -21.77 ± 24.909 | -16.63 ± 41.372 | -22.84 ± 22.934 |
| Day 30 | 0.92 ± 31.643 | -28.09 ± 21.846 | -22.80 ± 46.679 | -31.30 ± 26.785 |
| Day 60 | -4.29 ± 30.944 | -30.89 ± 26.802 | -26.11 ± 45.964 | -36.21 ± 22.036 |
| Day 90 | 4.35 ± 29.270 | -27.08 ± 25.260 | -24.93 ± 42.005 | -34.26 ± 25.027 |
| Day 104 | -2.41 ± 26.326 | -32.02 ± 30.286 | -25.99 ± 45.444 | -37.92 ± 30.801 |
| Day 120 | 0.22 ± 23.786 | -31.46 ± 27.979 | -30.26 ± 37.382 | -37.24 ± 25.389 |
| Day 150 | 4.02 ± 32.703 | -32.21 ± 26.140 | -21.59 ± 47.820 | -38.11 ± 24.508 |
| Day 180 | 5.45 ± 36.446 | -30.15 ± 25.578 | -25.46 ± 48.279 | -35.41 ± 25.123 |
Proportion of participants who attain lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines for their level of cardiovascular risk at Day 180 was calculated to evaluate the effect of inclisiran.
| Participants | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Proportion of Participants Who Attain Lipid Control Target Pre-specified by JAS 2017 Guidelines for Their Level of Cardiovascular Risk at Day 180 | 5 | 50 | 87 | 91 |
Number of participants by LDL-C levels was calculated to evaluate the effect of inclisiran.
| Participants | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium |
|---|---|---|---|---|
| Day 14: LDL-C <25 mg/dL | 0 | 1 | 5 | 10 |
| Day 14: LDL-C <50 mg/dL | 1 | 19 | 38 | 43 |
| Day 14: LDL-C <70 mg/dL | 3 | 29 | 56 | 66 |
| Day 14: LDL-C <100 mg/dL | 22 | 45 | 81 | 86 |
| Day 30: LDL-C <25 mg/dL | 0 | 6 | 14 | 20 |
| Day 30: LDL-C <50 mg/dL | 0 | 30 | 56 | 71 |
| Day 30: LDL-C <70 mg/dL | 3 | 40 | 74 | 80 |
| Day 30: LDL-C <100 mg/dL | 22 | 51 | 93 | 94 |
| Day 60: LDL-C <25 mg/dL | 0 | 6 | 14 | 23 |
| Day 60: LDL-C <50 mg/dL | 0 | 28 | 57 | 70 |
| Day 60: LDL-C <70 mg/dL | 5 | 37 | 77 | 79 |
| Day 60: LDL-C <100 mg/dL | 21 | 50 | 92 | 92 |
| Day 90: LDL-C <25 mg/dL | 0 | 2 | 12 | 21 |
| Day 90: LDL-C <50 mg/dL | 0 | 27 | 51 | 67 |
| Day 90: LDL-C <70 mg/dL | 1 | 35 | 74 | 80 |
| Day 90: LDL-C <100 mg/dL | 24 | 49 | 93 | 94 |
| Day 104: LDL-C <25 mg/dL | 0 | 6 | 22 | 27 |
| Day 104: LDL-C <50 mg/dL | 0 | 30 | 64 | 70 |
| Day 104: LDL-C <70 mg/dL | 4 | 38 | 82 | 80 |
| Day 104: LDL-C <100 mg/dL | 25 | 52 | 95 | 92 |
| Day 120: LDL-C <25 mg/dL | 0 | 9 | 25 | 32 |
| Day 120: LDL-C <50 mg/dL | 0 | 32 | 64 | 70 |
| Day 120: LDL-C <70 mg/dL | 3 | 39 | 82 | 81 |
| Day 120: LDL-C <100 mg/dL | 24 | 53 | 95 | 91 |
| Day 150: LDL-C <25 mg/dL | 0 | 5 | 24 | 31 |
| Day 150: LDL-C <50 mg/dL | 0 | 32 | 67 | 71 |
| Day 150: LDL-C <70 mg/dL | 2 | 41 | 81 | 81 |
| Day 150: LDL-C <100 mg/dL | 23 | 52 | 95 | 93 |
| Day 180: LDL-C <25 mg/dL | 0 | 7 | 13 | 26 |
| Day 180: LDL-C <50 mg/dL | 0 | 30 | 56 | 65 |
| Day 180: LDL-C <70 mg/dL | 2 | 40 | 78 | 80 |
| Day 180: LDL-C <100 mg/dL | 22 | 54 | 94 | 90 |
Collected over Adverse events were reported from first dose of study treatment up to a maximum duration of 360 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/57 (1.8%) | 6/57 (10.5%) | 32/57 (56.1%) |
| Inclisiran 100 mg | 0/55 (0%) | 2/55 (3.6%) | 38/55 (69.1%) |
| Inclisiran 200 mg | 0/101 (0%) | 7/101 (6.9%) | 59/101 (58.4%) |
| Inclisiran 300 mg | 0/99 (0%) | 7/99 (7.1%) | 59/99 (59.6%) |
| Event | Placebo | Inclisiran 100 mg | Inclisiran 200 mg | Inclisiran 300 mg |
|---|---|---|---|---|
| Angina unstableCardiac disorders | 1/57 | 1/55 | 0/101 | 1/99 |
| Radius fractureInjury, poisoning and procedural complications | 0/57 | 1/55 | 0/101 | 0/99 |
| Vitreous haemorrhageEye disorders | 1/57 | 0/55 | 0/101 | 0/99 |
| DeathGeneral disorders | 1/57 | 0/55 | 0/101 | 0/99 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/57 | 0/55 | 0/101 | 0/99 |
| Wound dehiscenceInjury, poisoning and procedural complications | 1/57 | 0/55 | 0/101 | 0/99 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/57 | 0/55 | 1/101 | 0/99 |
| Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/57 | 0/55 | 0/101 | 0/99 |
| Embolic cerebral infarctionNervous system disorders | 1/57 | 0/55 | 0/101 | 0/99 |
| Cardiac failure congestiveCardiac disorders | 0/57 | 0/55 | 0/101 | 1/99 |
| Event | Placebo | Inclisiran 100 mg | Inclisiran 200 mg | Inclisiran 300 mg |
|---|---|---|---|---|
| Diabetes mellitusMetabolism and nutrition disorders | 5/57 | 11/55 | 12/101 | 12/99 |
| PyrexiaGeneral disorders | 7/57 | 8/55 | 12/101 | 18/99 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 9/57 | 7/55 | 10/101 | 15/99 |
| COVID-19Infections and infestations | 2/57 | 8/55 | 5/101 | 6/99 |
| Vaccination site painGeneral disorders | 8/57 | 1/55 | 5/101 | 5/99 |
| Injection site reactionGeneral disorders | 2/57 | 3/55 | 12/101 | 6/99 |
| Back painMusculoskeletal and connective tissue disorders | 5/57 | 6/55 | 3/101 | 8/99 |
| MalaiseGeneral disorders | 6/57 | 1/55 | 2/101 | 7/99 |
| HeadacheNervous system disorders | 5/57 | 3/55 | 3/101 | 3/99 |
| DiarrhoeaGastrointestinal disorders | 1/57 | 4/55 | 5/101 | 1/99 |
| Age, Continuous(years) | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium | Total |
|---|---|---|---|---|---|
| Mean | 63.8 ± 11.12 | 62.7 ± 9.25 | 64.7 ± 10.57 | 63.0 ± 10.66 | 63.6 ± 10.46 |
| Sex: Female, Male(Participants) | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium | Total |
|---|---|---|---|---|---|
| Female | 18 | 19 | 21 | 22 | 80 |
| Male | 39 | 36 | 80 | 77 | 232 |
| Race/Ethnicity, Customized(Participants) | Placebo | 100 mg Inclisiran Sodium | 200 mg Inclisiran Sodium | 300 mg Inclisiran Sodium | Total |
|---|---|---|---|---|---|
| Japanese | 57 | 55 | 101 | 99 | 312 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2021 to primary completion in Apr 2022, 14 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 14 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran